Skip to main content
. Author manuscript; available in PMC: 2011 Feb 28.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Mar 26;64(6):1149–1155. doi: 10.1007/s00280-009-0977-x

Fig. 1.

Fig. 1

Expression of ribonucleotide reductase RR-M1 and -M2 in PMBCs in patients treated with infusional GTI-2040 combined with oxaliplatin and gemcitabine. All subjects received single-agent GTI-2040 at a dose of 3 mg/kg per day for the first 24 h, but patients 1, 2 were subsequently treated on dose level 1 and patients 3–5 were on dose level −1